SCHEMBL2593743

SCHEMBL2593743

C=CCN1CCSC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15330621 0.81
SCHEMBL11639745 0.79
Bromide SCHEMBL11738317 0.78 INMT (0.45)
SCHEMBL9350759 0.75
SCHEMBL7803036 0.72 CYP3A4 (0.35)
SCHEMBL9711159 0.71 ALDH1A1 (0.34)
SCHEMBL9711153 0.71 ALDH1A1 (0.34)
SCHEMBL10829163 0.71 CYP3A4 (0.34)
SCHEMBL8958844 0.70 CYP3A4 (0.46)
SCHEMBL462082 0.70 CYP3A4 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011135303-A2 UBIQUITINATION MODULATORS ITI SCOTLAND LIMITED (GB) 2011-11-03 WO disclosed
EP-0467599-B1 N-Alkyl thiazolidine derivatives SANTEN PHARMACEUTICAL CO LTD (JP) 1994-09-14 EP disclosed
US-5202342-A Usefule for treatment of liver disorders SANTEN PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 US disclosed
EP-0467599-A1 N-Alkyl thiazolidine derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 1992-01-22 EP disclosed